XSHE
300434
Market cap744mUSD
Oct 09, Last price
13.46CNY
1D
8.46%
1Q
12.54%
Jan 2017
-30.58%
IPO
117.49%
Name
Sichuan Goldstone Asia Pharmaceutical Inc
Chart & performance
P/E
41.08
P/S
5.21
EPS
0.33
Div yield, %
0.56%
Shrs. gr., 5y
0.40%
Rev. gr., 5y
-0.29%
Revenues
1.04b
-5.80%
Net income
132m
+43.44%
CFO
208m
+31.45%
Dividend
Jun 17, 20260.082 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, raw materials and health foods. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment. The company produces, installs, and maintains special equipment. It also imports and exports spare parts, raw, and auxiliary materials. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 1962 and is based in Hangzhou, China.
Key people
Yixi Kuai
Vice Chairman of the Board · since 2020
Jin Lou
Vice Chairman of the Board · since 2017
Qingguo Wang
Chief Financial Officer · since 2023
Vice President, Deputy General Manager, Secretary of the Board, Director · since 2023
Zhihao Wang
Vice President, Deputy General Manager · since 2023
Yiping Ma
Chairman of the Board, President, General Manager · since 2023
Xiaoxia Sheng
Vice President, Deputy General Manager, Director · since 2023
Liu Yang
Director · since 2017
Zhiyong Zheng
Director · since 2017
Youlong Jia
Independent Director · since 2023
Chuwang Liu
Independent Director · since 2023
Xiaowei Zhao
Independent Director · since 2023
Peng Zhong
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||